Investor Presentaiton

Continued solid momentum in Voice & Respiratory Care with 9% organic growth in Q3, driven by both Laryngectomy and Tracheostomy Voice & Respiratory Care performance 9 9 9 9 7 3 480 459 479 491 446 • Q3 2022/23 highlights Voice and Respiratory Care delivered 9% organic growth • . Laryngectomy delivered high single-digit organic growth, driven by growth in new patients in existing and new markets, as well as an increase in patient value driven by the Provox® Life™ portfolio Tracheostomy and ENT (Ear, Nose & Throat) delivered double-digit organic growth, with continued solid demand and positive impact from forward integration in key European markets All regions continued to contribute to growth led by Europe and solid contribution from Other developed markets and the Emerging markets The integration of Atos Medical IT and finance infrastructure is progressing well. Coloplast remains on track to deliver estimated run-rate operational synergies of up to DKK 100 million, with full impact from FY 2023/24 • In May, the integration of IT infrastructure was finalised. In addition, Coloplast's and Atos Medical's subsidiaries across a number of markets were merged into one legally entity during the quarter 8 Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23 Q3 22/23 Reported growth (%) Revenues (DKKm) Acquired growth impact (%) * Organic growth (%) * Voice and Respiratory Care acquired growth contribution to Group reported growth. Voice and Respiratory Care part of organic growth since February 1, 2023 Coloplast

View entire presentation